One potential solution to the Trump administration's more assertive posture on pharmaceutical pricing in benchmark countries like Australia is to raise the published list PBS price paid to manufacturers. Yet it could have unintended consequences.
A simple increase in published list prices could have unintended consequences
February 10, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Territory partnership backs digital health push for diabetes, kidney and heart care
July 9, 2026 - - Latest News -
It might make sense to follow the process, mostly, but no need to keep patients waiting
July 9, 2026 - - Latest News -
Illumina taps medtech leader to head Australia and New Zealand operations
July 8, 2026 - - Latest News -
PYC Therapeutics names Thomas Ulmer as new chief financial officer
July 8, 2026 - - Australian Biotech -
In a perfect world, the minister would not be in this position, and he might question the timeline
July 8, 2026 - - Latest News -
Aegros completes Australia’s second large scale plasma fractionation plant
July 8, 2026 - - Latest News -
'But I've said it's really important that these two drugs stay on the PBS'
July 7, 2026 - - Latest News

